Foundation Awards Two $100,000 Grants to Advance Gastric Cancer Research
The Gastric Cancer Foundation is committed to addressing a key funding gap in research: Very little funding is available to early- and... Read More
Foundation Awards New Grants to Researchers Pursuing Novel Approaches in Gastric Cancer
The biggest challenge facing researchers who have exciting but unproven ideas for fighting gastric cancer is raising the funds they need to... Read More
Nivolumab/Paclitaxel Combo Shows Antitumor Activity in EBV-Related, MSI-H, PD-L1+ Advanced Gastric Cancer
Opdivo combined with paclitaxel showed anti-tumor activity in a phase 1/2 study of gastric cancer patients with a variety of tumor markers,... Read More
Amgen’s Investigational Bemarituzumab Receives Breakthrough Therapy Designation
The FDA granted breakthrough therapy designation to an experimental drug from Amgen for patients with FGFR2b over expressing and HER2-negative gastric cancer.
Investigational Anti-PD-1 Agent Shows Potential for Treatment of Unresectable or Metastatic MSI-H/dMMR Solid Tumors
The novel checkpoint inhibitor HLX10 showed positive safety and efficacy in a phase 2 clinical trial in patients with microsatellite instability-high or... Read More
Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
A study found that patients with gastroesophageal junction cancer who were treated with surgery and chemoradiotherapy had significantly longer disease-free survival if... Read More
FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb’s Opdivo in combination with chemotherapy.
Heavy Alcohol Use Is Associated With Gastric Cancer
A study in the American Journal of Gastroenterology found an association between heavy alcohol use and an increased risk of gastric cancer.
Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy
A recent study found that patients over 70 with esophageal cancers benefited from “triple modality” surgery that included surgery, with five-year survival... Read More
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.